• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Orsini, PicnicHealth Partner to Improve Rare Disease Patient Care

by Syed Hamza Sohail 01/13/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

– Orsini, a leader in rare disease pharmacy solutions, announced today a new partnership with PicnicHealth, a health technology company dedicated to simplifying observational research. 

– This collaboration enables rapid development of drug-specific registries that combine real world drug data, curated electronic medical records (EMR) and patient-reported perspectives. The result is more comprehensive real-world data on approved therapies, providing deeper insights into patient treatment journeys and medication adherence to improve care for rare disease patients.

Enhancing Rare Disease Research Through Strategic AI-Driven Partnerships 

In 2024, PicnicHealth launched a life sciences research platform to streamline observational research and help life sciences companies achieve study endpoints. Leveraging advanced artificial intelligence (AI), the platform accesses universal patient records from consented individuals to capture relevant study data. This innovative approach enables the rapid development of drug-specific registries that integrate: 

– Real-world drug data 

– Curated electronic medical records (EMRs) 

– Patient-reported outcomes 

These registries enhance research efficiency and improve patient outcomes by delivering actionable insights. 

Similarly, Orsini introduced ORBIT™ (Orsini Rare Business Intelligence Technology), an AI-powered reporting and analytics platform designed to optimize care for rare disease patients. The collaboration between PicnicHealth and Orsini is poised to generate meaningful insights into patient adherence and long-term outcomes, fostering the success of specialized therapies within rare disease populations. 

To initiate this venture, PicnicHealth and Orsini partnered with AstraZeneca, a global biopharmaceutical leader, to support insights on WAINUA™ (eplontersen). WAINUA, an FDA-approved treatment for hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN or ATTRv-PN), is distributed exclusively through Orsini Specialty Pharmacy. 

Brandon Tom, CEO of Orsini, emphasized the significance of this collaboration, stating that adherence is critical for ensuring successful patient outcomes, particularly in rare disease communities. He highlighted that the partnership represents a meaningful step toward achieving Orsini’s mission to ensure no patient is left behind. 

WAINUA™: Important Safety Information 

Patients prescribed WAINUA should be aware of the following safety considerations: 

– Potential Side Effects:  

  – Low Vitamin A Levels: A common but serious side effect requiring vitamin A supplementation as directed by a healthcare provider. Patients should report vision issues (e.g., night blindness or dry eyes) to their physician, who may refer them to an eye specialist. 

  – Other Common Side Effects: Vomiting and decreased vitamin A levels. 

– Precautions: 

  – Pregnancy and Breastfeeding: WAINUA may alter vitamin A levels, potentially harming an unborn baby. Its effects on breast milk are unknown; discuss with a healthcare provider. 

  – Drug Interactions: Inform the healthcare provider about all medications, supplements, and vitamins, particularly vitamin A or beta-carotene supplements. 

Through these collaborative efforts, PicnicHealth, Orsini, and AstraZeneca are driving advancements in rare disease care and research, offering renewed hope to patients living with hATTR-PN.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance

Most-Read

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

CB Insights’ 2026 Digital Health 50 Reveals How Agentic AI Is Becoming the Clinical Provider and Medication Access Engine

Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

M&A: Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

CVS Rebrands Health Services Segment, Launches Model for Retail Pharmacy Reimbursement

CVS Health Formalizes Tax-Free Split-Off to Carve Out CVS Pharmacy by 2028

SAMHSA and ONC Invest $20M in Behavioral Health IT Initiative

ONC Finalizes HTI-5 Deregulatory Rule to Cut $1.55B in Health IT Compliance and Accelerate FHIR APIs

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |